HOME >> BIOLOGY >> NEWS
Scientists find hormone activity explains adolescent mood swings

The "raging hormones" of puberty are known to produce mood swings and stress for most teenagers, making it difficult to cope with this period of life. Until now, the specific causes of pubertal anxiety have not been identified, making it harder to understand and treat adolescent angst.

In the current edition of the journal Nature Neuroscience, researchers led by Sheryl S. Smith, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center, report findings demonstrating that a hormone normally released in response to stress, THP, actually reverses its effect at puberty, when it increases anxiety.

This hormone normally acts like a tranquilizer, acting at sites in the brain that "calm" brain activity. In the adult, this stress hormone helps the individual adapt to stress, with a calming effect produced half an hour after the event.

Specifically, the GABA-A receptor is the target for steroids, such as THP (or allopregnanolone), which reduce anxiety. GABA-A receptors calm activity in the brain. As such, they are the targets for most sedative, tranquilizing drugs.

One sub-type, GABA-A receptors containing the delta subunit, such as alpha4-beta2-delta, has the highest sensitivity to steroids. In order to study its role in puberty, the researchers used a mouse model that reliably predicts the human condition. In this rodent model, the alpha4-beta2-delta receptor normally has very low expression, but increases dramatically at the onset of puberty in the part of the brain that regulates emotion. Paradoxically, THP reduced the inhibition produced by these alpha4-beta2-delta GABA-A receptors, increasing brain activity to produce a state of increased anxiety. Stress also increased anxiety at puberty, due to the paradoxical effects of this hormone that is released by stress.

Dr. Smith and colleagues identified the site on human recombinant alpha4-beta2-delta GABA-A receptors that produced the anxiety respo
'"/>

Contact: Sheryl S. Smith
sheryl.smith@downstate.edu
516-353-4714
SUNY Downstate Medical Center
11-Mar-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: